Comparison Between Intravitreous Fluocinolone Acetonide Implant, Ozurdex Implant, and Cyclosporine in Treatment of Noninfectious Uveitic Macular Edema

Background: Communicable etiologies such as Toxocara canis tuberculosis, herpes virus, toxoplasmosis, syphilis, and Lyme disease, can cause secondary uveitis. Ocular inflammation is frequently accompanied by an underlying general disease, such as sarcoidosis, juvenile idiopathic arthritis (JIA), Vogt-Koyonagi-Harada (VKH), tubulointerstitial nephritis (TINU), inflammatory bowel disease and uveitis.Methods: A sum of ۶۰ eyes of ۴۵ uveitic participants were enlisted in our study. In ۱st group; ۲۰ eyes undergo an Intravitreous fluocinolone acetonide implant ۲nd group; ۲۰ eyes undergo an ozurdex implant. The ۳rd group of ۲۰ eyes undergo cyclosporine injection.Results: For our study, a sum of ۶۰ eyes from ۴۵ uveitic participants (۳۶ men, ۲۴ women) were enrolled. ۲۰ eyes from the ۱st group receive intravitreal fluocinolone acetonide implants. ۲۰ eyes from the ۲nd group receive Ozurdex implants. The ۳rd group of ۲۰ eyes received nine injections of cyclosporine at a dose of ۵ mg/kg/day, one dose every two weeks for three months, and subsequently one dose per month for three months.Conclusion: In order to reduce the negative outcomes of corticosteroids and other hazardous medications, this research showed cyclosporin injection could remain as a solitary treatment to manage uveitic ME related to noninfectious uveitis. Tiny subset of individuals, though, cannot tolerate the toxicity of cyclosporine, therefore it must be carefully monitored. The final management must be customized established regarding severity of illness, the risk/benefit ratio of each treatment, and the participant preferences.

کلیدواژه ها:

Intravitreous Fluocinolone Acetonide Implant ، Dexamethasone Implant ، Cyclosporine Injection ، Uveitic Macular Edema